Christina Ryder
Psychiatric/Mental Health · Collegeville, PANPI 1841955465
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.1% of the total across 442 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 26 manufacturers, the largest accounting for just 14.4% — the pattern of someone who eats at a lot of different presentations. Among psychiatric/mental health clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 442 payments — averaging $18.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
- Neurocrine Biosciences, Inc.$979
- Otsuka America Pharmaceutical, Inc.$867
- Johnson & Johnson$648
- Teva Pharmaceuticals USA, Inc.$572
- plus $3K from 20 others
What the payments were for
- Food & beverage$7,92898%
- Education$1532%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 98 | $1,162 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 46 | $1,031 |
| Neurocrine Biosciences, Inc. | 42 | $979 |
| Otsuka America Pharmaceutical, Inc. | 47 | $867 |
| Johnson & Johnson | 32 | $648 |
| Teva Pharmaceuticals USA, Inc. | 27 | $572 |
| Lundbeck LLC | 24 | $436 |
| Vanda Pharmaceuticals Inc. | 23 | $431 |
| Alkermes, Inc. | 17 | $407 |
| Axsome Therapeutics, Inc. | 19 | $403 |
| Corium, LLC | 14 | $237 |
| Supernus Pharmaceuticals, Inc. | 14 | $165 |
| Collegium Pharmaceutical, Inc. | 8 | $148 |
| Merck | 6 | $101 |
| E.r. Squibb & Sons, L.L.C. | 5 | $92 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $92 |
| Ironshore Pharmaceuticals Inc. | 3 | $66 |
| Almatica Pharma LLC | 3 | $54 |
| Vertical Pharmaceuticals, LLC | 2 | $43 |
| Idorsia Pharmaceuticals US Inc | 2 | $32 |
| Indivior Inc. | 1 | $29 |
| Jazz Pharmaceuticals Inc. | 1 | $23 |
| Noven Therapeutics, LLC | 1 | $20 |
| Tris Pharma Inc | 1 | $15 |
| Neos Therapeutics, LP | 1 | $14 |
| Sage Therapeutics, LLC | 1 | $14 |
How this compares
$8,081 in reported general payments places this provider in the 95th percentile of 1,041 psychiatric/mental health providers in Pennsylvania.
See all psychiatric/mental health providers in Pennsylvania →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 20 | $170,835 |
| VraylarCariprazine Hcl | 86 | $121,201 |
| Austedo XrDeutetrabenazine | 11 | $117,119 |
| Invega SustennaPaliperidone Palmitate | 24 | $70,913 |
| FanaptIloperidone | 13 | $45,417 |
| RexultiBrexpiprazole | 30 | $44,065 |
| Clozapine | 466 | $22,125 |
| TrintellixVortioxetine Hydrobromide | 16 | $8,358 |
| Aripiprazole | 218 | $6,972 |
| ConcertaMethylphenidate Hcl | 12 | $6,094 |
| Divalproex Sodium | 93 | $5,503 |
| Quetiapine Fumarate | 394 | $5,329 |
| Divalproex Sodium ErDivalproex Sodium | 170 | $4,357 |
| Paliperidone ErPaliperidone | 17 | $4,273 |
| Clonazepam | 366 | $3,803 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $979 | $170,83520 claims |
| AbbVieVraylar | $1,162 | $121,20186 claims |
| Teva Pharmaceuticals USA, Inc.Austedo Xr | $572 | $117,11911 claims |
| Johnson & JohnsonInvega Sustenna, Concerta, Risperdal | $648 | $79,80751 claims |
| Vanda Pharmaceuticals Inc.Fanapt | $431 | $45,41713 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $867 | $44,06530 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $92 | $8,35816 claims |
| Almatica Pharma LLCSertraline Hcl | $54 | $2,286274 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,041 psychiatric/mental health providers in Pennsylvania.
Other psychiatric/mental health in Collegeville
- Kimberly GarciaAllentown$573K
- Cortney SmithWashington$227K
- Britney KeplerPittsburgh$158K
- Kirstyn KamegBethel Park$136K
- Anna DipietroDowningtown$131K
- Deena MasciocchiLanghorne$71K
- Joseph GagnonChesterbrook$64K
- Michelle CohenWashington$62K
- Sharon KatzJenkintown$51K
- Jennifer BowmanCanonsburg$48K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.